Loading...
NPI 1619488418 · Frisco, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Supreme Medical Laboratories LLC is a clinical medical laboratory provider located in Frisco, Texas. This profile covers 31 Medicare and 67 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Supreme Medical Laboratories LLC |
| Address | 3803 Parkwood Blvd Ste 400 |
| City | Frisco |
| State | TX |
| ZIP | 75034 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 19, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $1.2M |
| Medicare | $648K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
31 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 320 | $440 | $139.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 3,130 | $30 | $106.3K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 2,660 | $30 | $90.3K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 280 | $290 | $80.4K |
| 81105 | The lab analyst performs the technical lab test to analyze the genes of the two common alleles of Human Platelet Antigen 1 (HPA–1), also called CD61 or ITGB3, using a specimen such as blood or… | 410 | $120 | $49.6K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 570 | $70 | $39K |
| 81291 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for 5,10–methylenetetrahydrofolate reductase, also known as MTHFR. | 430 | $60 | $27.2K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 40 | $590 | $24.7K |
| 81227 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 9, also known as CYP2C9. | 100 | $170 | $17.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 460 | $30 | $15.5K |
Showing 1–10 of 31
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 31 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
31 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 13 | 30 | 1,260 | $30 | $430.3K |
| 81249 | 17 | 20 | 80 | $590 | $319.2K |
| 87798 | 75 | 300 | 790 | $30 | $265.1K |
| 81223 | 25 | 30 | 70 | $450 | $197.4K |
| 87801 | 31 | 120 | 170 | $70 | $86.5K |
| G0483 | 144 | 170 | 150 | $240 | $84.9K |
| 87481 | 90 | 270 | 150 | $30 | $68.8K |
| 81105 | 1 | 10 | 410 | $120 | $49.5K |
| 87486 | 61 | 60 | 90 | $30 | $32.7K |
| 87581 | 65 | 70 | 80 | $30 | $32.2K |
Showing 1–10 of 31
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
67 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 5,240 | $70 | $366.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4,200 | $30 | $134.2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 940 | $140 | $131.2K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2,530 | $30 | $86.2K |
| 87632 | The lab analyst performs a test to identify a respiratory virus using an amplified nucleic acid probe technique. He may also use the multiplex reverse transcription technique. The provider does this… | 650 | $90 | $57.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 3,010 | $10 | $42.2K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 2,140 | $20 | $38.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,040 | $40 | $36.2K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 1,400 | $20 | $23.9K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 1,050 | $20 | $21.9K |
Showing 1–10 of 67
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
67 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 58 | 340 | 400 | $50 | $553.5K |
| 87632 | The lab analyst performs a test to identify a respiratory virus using an amplified nucleic acid probe technique. He may also use the multiplex reverse transcription technique. The provider does this… | 5 | 20 | 180 | $170 | $362.6K |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 31 | 40 | 100 | $230 | $335.3K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 80 | 160 | 200 | $280 | $321.8K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 36 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 160 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 160 | 300 | 410 | $20 | $223.4K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 79 | 150 | 320 | $20 | $184K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 49 | 110 | 360 | $40 | $174.9K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 42 | 100 | 650 | $50 | $161.3K |
Showing 1–10 of 67
Other providers in the same ZIP code as Supreme Medical Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ayass Lung Clinic, PLLC | TX | Clinical Medical Laboratory | $552K | $30.5K |
| Baylor Surgicare At Blue Star, LLC | TX | Ambulatory Surgical Clinic/Center | $563.4K | $0 |
| Fareha Kazi | TX | Internal Medicine Physician | $440K | $0 |
| Mark Mcquaid | TX | Surgery Physician | $371.1K | $0 |
| David Keelen | TX | Pain Medicine Physician | $324.2K | $0 |
| John Skiendzielewski | TX | Phlebology Physician | $280.8K | $0 |
| Brent Stevenson | TX | Sleep Medicine (Psychiatry & Neurology) Physician | $272.6K | $0 |
| Annaliese Majeed | TX | Physician Assistant | $222.3K | $0 |
| Andrew Morchower | TX | Interventional Pain Medicine Physician | $205.9K | $0 |
| Timothy Rodgers | TX | Dermatology Physician | $137.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.